Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Carlos Oscar Ontiveros
Observed names:
Carlos O Ontiveros,
Carlos O. Ontiveros
Institution:
The University of Texas at San Antonio Health Science Center
Observed institutions:
Dartmouth College,
Scripps Research Institute,
Texas Biomedical Research Institute,
The University of Texas at San Antonio Health Science Center,
Dartmouth Cancer Center,
The University of Texas at San Antonio
show all 6
ORCID:
0000-0002-6079-5971
Observed ORCID:
0000-0002-6079-5971
OpenAlex ID:
A5029843433
Reversing Post-Infectious Epigenetic-Mediated Immune Suppression
2021
·
Abhimanyu
, Carlos O. Ontiveros
, et al.
·
Frontiers in Immunology
·
47
PDF
Considerations and Approaches for Cancer Immunotherapy in the Aging Host
2023
·
Carlos O. Ontiveros
, Clare E. Murray
, et al.
·
Cancer Immunology Research
·
17
PDF
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling
2025
·
Carlos O. Ontiveros
, Myrna G. Garcia
, et al.
·
Nature Communications
·
6
PDF
Cutting Edge: Cytosolic Receptor AIM2 Is Induced by Peroxisome Proliferator-activated Receptor γ following Mycobacterium tuberculosis Infection of Human Macrophages but Does Not Contribute to IL-1β Release
2024
·
Eusondia Arnett
, Jade Wolff
, et al.
·
The Journal of Immunology
·
6
PDF
Genomic and phenotypic analyses suggest moderate fitness differences among Zika virus lineages
2023
·
Glenn Oliveira
, Chantal B.F. Vogels
, et al.
·
PLoS neglected tropical diseases
·
3
PDF
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production
2026
·
Clare E Murray
, Carlos O Ontiveros
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Characterization of AIM2 expression in human macrophages during M. tuberculosis infection
2019
·
Carlos Oscar Ontiveros
, Eusondia Arnett
, et al.
·
The Journal of Immunology
·
1
Telmisartan improves chemotherapy and immune checkpoint blockade efficacy by enhancing mitotic catastrophe and inducing tumor immunogenicity 3238
2025
·
Clare Murray
, Bernice Leung
, et al.
·
The Journal of Immunology
PDF
Tumor PDL1-associated DNA damage response inhibitor (DDRi) resistance is STING dependent 3647
2025
·
Anja N. Holtz
, Clare Murray
, et al.
·
The Journal of Immunology
PDF
Melanoma cell-of-origin (melanocyte) PDL1 deletion delays melanomagenesis that is overcome by UVB-induced immunosuppression through IFN-I signaling 2676
2025
·
Carlos Oscar Ontiveros
, Nathaniel Spicer
, et al.
·
The Journal of Immunology
PDF
Melanocyte PDL1 inhibits MITF expression to maintain low lysosomal activity, associated with promoting NRAS mutant melanoma lung metastases 2725
2025
·
Haiyan Bai
, Carlos Oscar Ontiveros
, et al.
·
The Journal of Immunology
PDF
Adipocyte PDL1 depletion sensitizes NRASQ61R-mutant melanoma to anti-PDL1 immune checkpoint blockade (ICB) 3414
2025
·
Bernice Leung
, Carlos Oscar Ontiveros
, et al.
·
The Journal of Immunology
PDF
PD-L2 blockade elicits IL-17-induced IFNγ to treat melanoma in the aged host through CD8+ T and gd T cell effects 4160
2025
·
Christopher Tanner
, Carlos Oscar Ontiveros
, et al.
·
The Journal of Immunology
PDF
Melanocyte PDL1 promotes early tumor progression in a novel autochthonous NRAS-mutant melanoma model
2023
·
Carlos Oscar Ontiveros
, Tiffany Chen
, et al.
·
The Journal of Immunology
PDF
Pharmacologic tumor PDL1 depletion as a novel approach to overcome treatment resistance
2023
·
Clare Murray
, Haiyan Bai
, et al.
·
The Journal of Immunology
PDF
Show more works
View as search
Works count:
15
Citation count:
81
H-index:
4
I10-index:
2
Year
Topic
Type